NEW DELHI: Mumbai’s KEM and Nair hospitals have begun the preliminaries of conducting the Oxford University-Astra Zeneca Covid-19 vaccine trial.
The vaccine has been named as Covishield, its technical name is ChAdOx1 nCoV-19.

Here is a look at the details on the trial’s nature and the selection criteria —

Phase II/III trial’s purpose

  • To see if a vaccine made from the weakened virus that causes common cold in chimps can protect from Covid.
  • The tech, developed at Oxford’s Jenner Institute, has been used to make vaccines against flu, Zika and MERS
  • A total of 17 institutions in India to participate in trial, to be conducted by Serum Institute of India, Pune.
  • The siz of the sample would be 1,600 people — 400 for immune response study and 1,200 to gauge safety.

Who can pariticpate

  • Anyone between the age 18 to 99 years is eligible to participate. Both male and female and permitted to take part in the trial.
  • The participant should be a healthy adult as determined by medical history. Informed consent a must.
  • He/She must be resident of study area for ease of sample collection, visits.
  • Women of childbearing potential must have a negative urine pregnancy test within 24 hours before vaccine administration.

Who cannot take part

  • Person with acute illness with or without fever at the time of vaccine administration or with history of lab-confi rmed Covid-19 in household or work contact.
  • Has developed antibodies for SARS-CoV-2 With history of severe allergic reactions after previous vaccinations.
  • Has confirmed or suspected condition with impaired/altered function of immune system.

Where to contact

  • Mumbai — King Edward Memorial Hospital (022-24133767, 24174420); BYL Nair Hospital (022-23027644, 45 (direct))
  • Pune — BJ Medical College, Bharati Vidyapeeth, Jehangir Hospital
  • Wardha — Jawaharlal Nehru Medical College
  • Nagpur — Mahatma Gandhi Institute of Medical Science


Source link